Hengrui Showcases Innovative Cancer Research at ESMO 2026 Conference in Madrid

Hengrui's Breakthrough Research at ESMO 2026

The 2026 European Society for Medical Oncology (ESMO) Congress recently concluded in Madrid, showcasing impressive advancements in oncology, particularly by Hengrui Pharma. As a leader in pharmaceutical innovation from China, Hengrui presented a record 64 research studies at the congress, highlighting their significant role in cancer treatment development and their growing international influence.

Commitment to Oncology

Hengrui Pharma has established a strong reputation for its commitment to oncology, consistently investing in research and development (R&D) over the years. This year's congress accepted 64 of Hengrui’s studies, including three distinguished presentations, three rapid oral presentations, 32 posters, and 26 electronic posters. The research spanned over ten types of cancers, such as gastrointestinal, lung, and breast cancers, alongside gynecological, genitourinary, and various tumor types, covering vital supportive care considerations. Notably, among these presentations were 21 innovative drugs developed in China, featuring nine already approved and 12 candidates currently under investigation.

Dr. Karen Atkin, Hengrui's Global Business Strategy and Product Portfolio Director, expressed that ESMO serves as an essential platform for scientific exchange in oncology. “We are pleased to share our latest findings and engage with peers worldwide about emerging scientific advances and potential areas for collaboration,” she stated.

Innovation and Research Contributions

Hengrui Oncology's participation in the ESMO congress for 11 consecutive years emphasizes the firm’s dedication to advancing cancer treatments. Since 2023, the company has unveiled nearly 200 research results at this esteemed gathering, underscoring its leadership in oncology innovation. The continuous push for R&D has led to Hengrui launching 14 Class 1 innovative oncology drugs in China alone by mid-2026, which showcases the company’s commitment to addressing critical unmet medical needs.

Hengrui's R&D strategy emphasizes four key pillars for the development of innovative therapies: precision therapy, immunotherapy, targeted therapy, and supportive care treatments. Engaging with cutting-edge technologies, including drug discovery via artificial intelligence (AI), enhances their efficiency and adaptability in the changing landscape of drugdevelopment.

Global Presence and Partnerships

With a robust international presence, Hengrui operates a network of 15 R&D sites across Asia, Europe, North America, and Australia. This extensive setup facilitates their ability to conduct multicenter international clinical trials for various innovative programs. The company actively seeks collaborative relationships, such as external licensing and joint development, to foster worldwide collaboration in oncology projects, pushing for faster access to innovative therapies in global markets.

Health-Centric Philosophy

A patient-centric philosophy continues to drive Hengrui’s innovation approach. Looking ahead, Hengrui is poised to continue leveraging its innovations by introducing more Chinese-developed drugs to global markets, thereby expanding treatment options for cancer patients worldwide. Their ongoing commitment aims not just to solve clinical needs but also to contribute significantly to the global fight against cancer through the potency of Chinese scientific innovation.

In summary, the significant presence of Hengrui Pharma at the ESMO 2026 Conference not only highlights its impressive research capabilities but also solidifies its role as a leader in the global oncology field. The company remains dedicated to offering novel treatment solutions to enhance patient care and outcomes around the world.